Affimed (NASDAQ:AFMD) Stock Passes Below Two Hundred Day Moving Average – Here’s Why

Affimed (NASDAQ:AFMD)’s share price crossed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $3.13 and traded as low as $0.97. Affimed shares last traded at $1.00, with a volume of 183,040 shares.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on AFMD shares. Cantor Fitzgerald restated an “overweight” rating on shares of Affimed in a research note on Tuesday, November 19th. Wells Fargo & Company dropped their price objective on shares of Affimed from $20.00 to $15.00 and set an “overweight” rating for the company in a research report on Thursday, December 12th. Stifel Nicolaus lowered their price objective on Affimed from $5.00 to $4.00 and set a “hold” rating for the company in a research report on Friday, November 15th. Finally, HC Wainwright restated a “buy” rating and set a $10.00 target price on shares of Affimed in a research report on Tuesday, December 10th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $13.50.

Affimed Stock Down 2.9 %

The firm has a 50-day moving average price of $1.67 and a two-hundred day moving average price of $3.13. The company has a current ratio of 1.93, a quick ratio of 1.93 and a debt-to-equity ratio of 0.13.

Hedge Funds Weigh In On Affimed

Several hedge funds have recently modified their holdings of AFMD. Jane Street Group LLC acquired a new stake in Affimed in the third quarter valued at $44,000. FMR LLC increased its stake in shares of Affimed by 30.0% during the third quarter. FMR LLC now owns 17,696 shares of the biopharmaceutical company’s stock worth $59,000 after purchasing an additional 4,086 shares during the period. Intellectus Partners LLC lifted its holdings in Affimed by 12.2% during the 3rd quarter. Intellectus Partners LLC now owns 94,361 shares of the biopharmaceutical company’s stock worth $317,000 after purchasing an additional 10,250 shares during the last quarter. Finally, Point72 Asset Management L.P. boosted its position in shares of Affimed by 4.6% in the third quarter. Point72 Asset Management L.P. now owns 342,856 shares of the biopharmaceutical company’s stock valued at $1,152,000 after acquiring an additional 15,108 shares during the period. Institutional investors own 30.82% of the company’s stock.

About Affimed

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.